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Abstract 
Objective: It is uncertain whether persons with chronic widespread pain (CWP) experience premature 
mortality. Using the largest study conducted, we determine whether such a relationship exists,  
estimate its magnitude and establish what factors mediate any relationship. 
Methods: UK Biobank, a cohort study of 0.5 million people aged 40-69 years, recruited throughout 
Great Britain 2006-10. Participants reporting “pain all over the body” for >3 months were compared 
with persons without chronic pain.. Information on death (with cause) was available until mid-2015. 
We incorporated these results in a meta-analysis with other published reports to calculate a pooled 
estimate of excess risk.. 
Results: 7130 participants reported CWP and they experienced excess mortality (Mortality Risk Ratio 
2.43, 95% Confidence Interval 2.17, 2.72). Specific causes of death in excess were cancer (1.73adjusted 
age and sex; 1.46, 2.05); cardiovascular (3.24adjusted age and sex; 2.55, 4.11); respiratory (5.66adjusted age and sex; 
4.00, 8.03); and other disease-related causes (4.04adjusted age and sex; 3.05, 5.34). Excess risk was 
substantially reduced after adjustment for low levels of physical activity, high body mass index (BMI), 
poor quality diet and smoking. In meta-analysis, all studies showed significant excess all-cause ( 
combined estimate  1.59 (1.05, 2.42)). cardiovascular and cancer mortality. 
Conclusions: Evidence is now clear that persons with CWP experience excess mortality. UK Biobank 
results considerably reduce uncertainty around the magnitude of excess risk, and are consistent with 
the excess being explained by adverse lifestyle factors, which could be targeted in the management 
of such patients. 
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Introduction 
 
Persons with CWP, the characteristic symptom of fibromyalgia, have been reported to experience 
premature mortality. The original observation, in a UK study, found 30% excess mortality was 
explained primarily by increased cancer incidence and reduced survival [1,2]. A subsequent UK study, 
confirmed the 30% excess mortality, primarily from increased cancer and cardiovascular deaths [3]. 
Studies to identify the mediators of such a relationship have focussed on low levels of physical activity, 
since the specific cancers contributing to excess mortality (female breast, prostate and colon) have 
been linked to low physical activity [4,5]. It has been hypothesised that CWP may lead to low levels of 
physical activity and this was confirmed by a longitudinal study [6]. Further studies have suggested 
additional lifestyle mediators of excess mortality: overweight has been shown to predict CWP onset 
and persistence [7,8]; persons with CWP have been reported as more likely to smoke and women with 
CWP have been shown to have poorer quality diet [9].  
However not all studies conducted have found an excess mortality amongst persons with CWP. Meta-
analyses have reported considerable heterogeneity which has been attributed to differences in study 
populations, follow-up time, pain phenotype, methods of analysis and use of confounding factors 
[10,11]. Currently there is considerable uncertainty as to whether there is an excess mortality risk. It 
is important to determine whether an excess risk exists and if so to quantify it, since there remains 
the potential, as part of managing patients with CWP or fibromyalgia, to modify the mediators of any 
excess risk.  
 
We therefore now report on the largest study to examine the relationship between chronic 
widespread pain and mortality experience, and with considerably more detailed information on 
potential mediators of any excess risk. Further we include these results in a meta-analysis, with other 
published reports,  to evaluate the coherence of evidence.  
 
Methods 
UK Biobank 
Detailed methods used by UK Biobank have been published previously [12] and we provide only 
summary details of relevance to the current analysis. The study aimed to recruit around half a million 
persons aged 40-69 years who were registered with a general practitioner within the NHS. 
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Approximately 9.2 million invitations were issued, between 2006-10, to people living within 25 miles 
of one of 22 assessment centres throughout Great Britain.  
At the assessment centre, participants completed questionnaires including items on lifestyle and 
environment. Information on pain was collected by means of a touch screen questionnaire. 
Participants were asked “In the last month have you experienced any of the following that interfered 
with your usual activities?” If they answered positively, they were then provided with a list which 
included individual regional pain sites, or alternatively they could choose the response “pain all over 
the body”. Subjects who reported “pain all over the body” were not offered the option of choosing 
any further regional sites. Respondents were asked whether the reported pain had lasted at least 
three months and those with “pain all over the body” which had lasted three months were defined as 
having chronic widespread pain (CWP). Participants were identified on the Office for National Statistics 
(ONS) records. ONS collects information on cause of death from civil registration records. For 
registered deaths, the underlying cause of death is derived from the sequence of conditions leading 
directly to the death and is recorded on the death certificate.  The current analysis uses data on vital 
status up to August 2015. 
The determinants or exposures which we considered in terms of mediating any relationship between 
CWP and mortality were focussed on factors potentially modifiable as part of the management of 
CWP:  
• age (in five year groups) and sex,  
• body mass index (BMI), derived from measured height and weight, categorised according to 
standard cut-offs of the World Health Organisation. 
• physical activity: minutes of walking per week (“In a typical week, on how many days did you 
walk for at least 10mins  at a time” and “How many minutes did you usually spend walking on 
a typical day?”); minutes of moderate activity per week (“In a typical week, on how many days 
did you do 10mins or more of moderate physical activities like carrying light loads, cycling at 
a normal pace (do not include walking)”  and “How many minutes did you usually spend doing 
moderate activities on a typical day ?” ); minutes of vigorous activity per week (as before but 
vigorous defined as “activities that make you sweat or breathe had such as fast cycling, 
aerobics, heavy lifting”. These were categorised as nil and then by quartiles. 
• Diet: Participants were asked (i) “On average how many heaped tablespoons of cooked 
vegetables would you eat per day?  (Do not include potatoes.)” (ii) “On average how many 
heaped tablespoons of salad or raw vegetables would you eat per day?  (Include lettuce and 
tomato in sandwiches)” (iii) “About how many pieces of fresh fruit would you eat per day?” 
 5 
 
(iv) “About how many pieces of dried fruit would you eat per day?” Total daily “portions” of 
cooked vegetables, raw vegetables, salad consumption were calculated and re-coded as 
quintiles. Frequency of alcohol consumption was determined with response categories: 
Never; Daily or almost daily; Three or four times a week; Once or twice a week; One to three 
times a month; Special occasions only. The latter two categories were combined into “Less 
frequently than once or twice per week” 
• Smoking status; a history of smoking was recorded which allowed us to classify respondents 
as current , never (or very rare) or ex-smokers, the latter group being divided into ex-regular 
and ex-occasional smokers.   
UK Biobank Analysis 
We used Poisson regression models, with robust estimation of standard errors to model the 
relationship between CWP and all-cause mortality, adjusted for age-group and sex. We tested and 
confirmed that the mediating variables were not collinear. We compared persons with CWP to 
persons who did not report any chronic pain. We additionally examined specific major causes of death 
as outcomes including cardiovascular disease, respiratory disease and cancer. We report the MRiR 
including all deaths in the follow-up period, but exclude deaths in the first two years of follow-up from 
all subsequent analyses, since CWP may be a manifestation of an existing illness. Starting with a basic 
model containing CWP, age-group and sex, we added, individually, lifestyle factors or markers which 
could possibly mediate any observed relationship. We then added all such potential mediators to a 
final model.  Associations are expressed as Mortality Risk Ratios (MRiR) with 95% Confidence Intervals 
(CI).  
Meta-analysis 
We used (in a modified way) and updated a search conducted by Smith et al [10] which identified 
studies examining the relationship between chronic pain and/or widespread pain and mortality.  
Although their review focussed generally on chronic pain, our update focussed only on studies 
examining widespread pain or chronic widespread pain. A second difference is that although previous 
meta-analyses extracted effect measures which were maximally adjusted for potential confounding 
factors we have extracted data that is (as close as possible) only adjusted for age and sex. The 
difference is that we are answering the question “Do persons with CWP experience excess mortality 
(in comparison to those without chronic pain)” whereas using fully-adjusted effect measures  is 
answering the question of whether the report of pain (per se) is associated with excess mortality. Thus 
the data on effect on measures extracted from studies which they identified as eligible, may be 
different.  
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We re-ran the published search strategy (in Appendix S1 of the original meta-analysis) from January 
2014 (in order to ensure that articles published close to the time of the previous search were not 
missed) to January 2017.  
Studies were eligible for the current meta-analysis provided that they: 
• Were observational studies 
• Sampled from a population sampling frame (or an approximation to such) 
• Identified persons with widespread pain (WP) or chronic widespread pain (including 
fibromyalgia) and a comparison group of persons without such pain. The definition of 
widespread pain should involve recognised criteria or the reporting of pain all over the body. 
• Provided either a Mortality Rate Ratio (MRtR) or Mortality Risk Ratio (MRiR) quantifying the 
relationship between WP or CWP and mortality 
• Were published as a manuscript in English  in a peer-reviewed journal 
Identified abstracts were screened by two authors and any disagreement resolved by discussion.  We 
also checked studies included in the meta-analysis by Smith et al [10] to determine that they met the 
above eligibility criteria. Meta-analysis was conducted using a random effects model, to reflect known 
differences in studies including geographical location, phenotypes and follow-up.  The effect measures 
extracted from the eligible studies (MRrR or MRiR) were as closely as possible only adjusted for age 
and sex. In the meta-analysis, conducted using RevMan software, MRR has been used to signify the 
combined estimates using MRtR and MRiR. Sources of heterogeneity in effect measures were 
explored, specifically in relation to the geographical area in which the study was conducted and 
prevalence estimate. 
Results 
UK Biobank 
 
From 502,627 UK Biobank participants, 2193 (0.4%) did not answer the pain questions and are 
therefore excluded from this analysis. Amongst the remaining 500,434 persons ,, 7130 reported CWP 
(prevalence 1.4%) while 281,718 reported that they did not have  any chronic pain. These two sub-
cohorts are the study population for the current analysis and their characteristics are shown in Table 
1.  The CWP and the “no chronic pain” groups had the same median age (58 years). Persons with CWP 
were less likely to be male (36.3% v. 50%); were more likely to be heavier than normal weight (80.4% 
v. 63.5%), be a current smoker (18.6% v. 9.3%) and not to drink any alcohol (22.7% v. 6.7%). They also 
undertook physical activity less often,  In total there were 12,799 deaths in the study population within 
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the period of observation: 7486 (58%) classified as being due to cancer, 2691 (21%) cardiovascular 
disease, 728 (6%) respiratory disease, 436 (3%) due to external causes, and 1458 (11%) were classified 
as 'other’. 
 
After adjusting for age and sex, participants with CWP had a more than two fold risk of dying in the 
follow-up period (MRiR 2.56, 95% CI (2.32,2.82)), an excess which remained largely unchanged when 
deaths occurring in the first two years of follow-up were excluded (2.43; 2.17, 2.72). Deaths occurring 
in the first two years are excluded from all further analyses. Specific causes of death in excess were 
cancer (1.73 adjusted age and sex; 1.46, 2.05); cardiovascular (3.24 adjusted age and sex; 2.55, 4.11); respiratory (5.66 
adjusted age and sex; 4.00, 8.03); and other disease-related causes (4.04 adjusted age and sex; 3.05, 5.34), while the 
excess of deaths from external causes was not statistically significant (1.55 adjusted age and sex; 0.68, 3.49). 
 
We then examined to what extent the factors which were identified as being associated with pain 
status, also predicted death in the period of follow-up (Table 2). Age-adjusted risk of death was lower 
in women (MRiR 0.58 (0.56, 0.60). Age and gender adjusted risk was higher in obese participants (35-
39 kgm-2 v. normal weight 5.54  (5.08, 6.03), ≥40kgm-2 9.02 (8.23, 9.89) those who reported no walking 
(v. 1-100 mins/week: 4.15 (3.77, 4.57) or no moderate physical activity (v. 1-60 mins/week: 2.95 (2.74, 
3.19). Risk of death was also higher in smokers (current smokers  2.54 (2.39, 2.70), ex-smokers 1.44 
(1.36, 1.52)), and persons who reported never drinking alcohol (v. daily drinkers 6.18 (5.68, 6.73).  
 
Finally, we tested to what extent adjusting the risk models for these measured lifestyle variables 
attenuated the relationship between CWP and excess mortality (Table 3). Such attenuation would be 
consistent with the effects being mediated through such variable(s). When we did this, each class of 
variable (physical activity, BMI, smoking, diet including alcohol) when added to the model containing 
only pain status (CWP/no chronic pain), age-group and sex resulted in a small attenuation of effect 
from a MRiR of 2.4 to MiRRs in the range 2.0 to 2.2. However when all such potentially mediating 
variables were entered in to the model the MiRR reduced to 1.47 (1.24, 1.73). In cause-of-death 
specific models with potential mediating variables there remained an excess risk of cardiovascular 
1.99 (1.41, 2.80), respiratory 1.91 (1.08, 3.36) and “other disease” deaths 2.14 (1.42, 3.21) but the 
there was no longer an excess risk of cancer death 1.06  (0.82, 1.38) and external deaths 1.01 (0.30, 
3.40). 
 
Meta-analysis 
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Our search identified 3171 unique publications, of which 15 proceeded to abstract screening and one 
to full-text screening and subsequent inclusion [12]. Of the five studies included in the meta-analysis 
of Smith et al [10], one did not meet eligibility criteria for the current meta-analysis [13], since the 
pain phenotype did not include any measure of “widespreadness”. Instead the phenotype examined 
was multiple joint pain. Thus a total of six studies (including the current analysis) were eligible for the 
current meta-analysis [1,3,12,14,15]. Characteristics of studies identified as eligible are given in Table 
4. One study presented data only to one decimal place and thus in the meta-analysis was identified as 
having a non-symmetrical log-transformed confidence interval [3]. We therefore contacted the first 
author of the publication and they provided more precise data (for analyses only adjusted for age and 
sex).  Eligible studies included 580, 020 participants from three European countries (Norway, Sweden 
and the United Kingdom). There was significant heterogeneity between studies: I2 = 98% for all-cause 
mortality, 95% for cardiovascular, 96% for respiratory and 91% for cancer (all p<0.001). All studies 
showed significant excess of all-cause mortality and the combined estimate of this was 57% (MRR 
1.57; 1.06, 2.33). For cardiovascular mortality, three out of five studies showed a significant 
association and the combined estimate of this was 63% (1.63; 0.98, 2.70). For respiratory mortality, 
only one out of three studies showed a significant excess mortality and there was considerable 
uncertainty around the pooled estimate of excess risk (1.70; 0.45, 6.45). For cancer, three out of five 
studies showed significant excess mortality and the pooled estimate was 51% (1.51; 1.06, 2.13) (Figure 
1). 
We investigated the source of heterogeneity with respect to the relationship between CWP and all-
cause mortality. When restricted by geographical area, the meta-analysis showed that considerable 
heterogeneity was present in studies conducted in Great Britain (I2=90%)(MRR 1.60; 1.06,2.42) but 
not in in studies conducted in Scandinavia (I2=0%) (MRR 1.06; 1.02,1.10). Similarly when analysis was 
restricted to those studies with prevalence of CWP in the 10-20% mid-range i.e. excluding those with 
the extreme prevalence estimates,  there was no evidence of heterogeneity (I2=0%)(MRR 1.30, 1.07-
1.58). 
 
Discussion 
Using data from UK Biobank, involving over half a million study participants, we have demonstrated 
that persons with CWP have an important excess of risk of dying in the medium and long-term. This 
excess risk was evident across all disease and non-disease categories. The meta-analysis of this 
relationship, shows that all six studies conducted find excess mortality, and estimates the excess risk 
across all studies at 59%, although there is significant heterogeneity. Similar excesses of cancer and 
cardiovascular mortality are observed. In UK Biobank, adjustment for lifestyle factors substantially 
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reduced the excess risk and this observation is consistent with them mediating the relationship 
between CWP and mortality   
Methodological issues 
The main strengths of UK Biobank in addressing this question   include that it uses a  sampling frame  
which is considered to have almost complete population coverage2. Although the participation rate 
was low (5.5%), we have previously published an analysis which demonstrates that the prevalence of 
regional pains in UK Biobank is very similar to more traditional pain epidemiological studies with 
higher participation, and that the study reproduces known relationships with aetiological factors. The 
large sample has allowed us to examine specific causes of death, to exclude deaths within two years 
of the assessment (since widespread pain may be a manifestation of a disease linked to death e.g. 
metastatic cancer) and consider the role of mediating factors. 
The phenotype used in studies which have examined the relationship with mortality has varied 
considerably. They have included WP according to the definition within the American College of 
Rheumatology (ACR) criteria (1990) for fibromyalgia [1,3], and modifications of the ACR 1990 FM 
criteria in terms of pain timing and distribution [12,15] or bespoke definitions to capture 
“widespreadness” [14]. The comparison populations also differ: persons who are free of pain [1,3,14], 
free of chronic pain [15] or who simply do not meet the phenotype [12] are variously used.  Some 
studies had an additional criterion that WP required to be chronic, although studies of widespread 
pain have shown that the vast majority of persons with WP report chronic symptoms (81% in UK 
Biobank).   These have resulted in prevalence proportions within population-based studies of between 
1.4-23.1% and suggest important differences in the symptomatic populations studied. Interestingly 
the study with the highest prevalence [12] reported a markedly lower excess risk of mortality.  UK 
Biobank has used the most stringent definition, which has resulted in a prevalence similar to that of 
fibromyalgia [16], and across all-cause and disease-specific mortality reports some of the highest 
excess mortality. This is consistent with the hypothesis that the greatest excess mortality is amongst 
those with the more severe symptoms. Sensitivity analyses confirmed that heterogeneity in risk 
estimates was indeed partly explained by differences in prevalence, as well by geographical area.   
We have approached the analysis in a different way to some previous studies on this topic. We 
adjusted for the confounding factors of age and sex. Given that the question we are asking is “Do 
patients with CWP experience prematurely mortality?” we believed that no further adjustment should 
be made.  However when excess mortality is observed it is of relevance to examine mediators – since 
                                                          
2 http://www.adls.ac.uk/department-of-health/gp-patient-register-dataset/?detail  
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these can become targets for intervention. Previous studies have identified lack of physical activity 
and poor quality diet as the variables which may explain a relationship. UK Biobank has a rich source 
of data to allow the assessment of these potential mediators. They nevertheless represent markers of 
these lifestyle factors rather than comprehensive assessments. Despite this, adjustment for these 
lifestyle markers almost completely explained cancer and “non-disease” excess mortality and 
explained 56% , 80% and 62% of the excess mortality for cardiovascular, respiratory and “other-
disease”, respectively.  
 
Comparison with other studies and coherence of evidence 
UK Biobank has provided results which are generally consistent with previously conducted studies. For 
cardiovascular mortality it has provided the largest estimate for excess mortality. It is the first study 
to suggest a relationship between CWP and excess mortality from respiratory disease. 
The meta-analysis of Smith et al [10] conducted on this topic chose to extract the most fully-adjusted 
model available in included studies which means that this examines a subtly different question of 
whether pain directly increases mortality risk (independent of any lifestyle, psychosocial or clinical 
factors)3. We believe that the most clinically relevant question for clinicians managing patients with 
WP/CWP or fibromyalgia is what factors can be modified which could reduce any excess mortality 
which such patients experience. We also excluded one study included in the previous meta-analysis. 
The study of Macfarlane et al [13] was not eligible for this analysis as it examined the mortality 
consequences of multi-joint pain (at least 4 joints). There was no requirement for pain to be 
widespread. All included studies had some requirement for the pain to be widespread or for the 
participant to endorse that the pain was all over their body. Even if the study of Macfarlane et al [13], 
which did not find any excess mortality MRiR (0.86; 0.74,1.01), had been included in the meta-analysis, 
the combined estimate would still have suggested an important excess. Exclusion of a phenotype that 
excludes a measure of “widespreadness” is supported by a proposed modification to the 2011 
research criteria for fibromyalgia which requires that multi-site pain is also widespread across the 
body [17]. The meta-analysis of Åsberg et al [18] concluded that “pooled data gave no evidence for a 
higher mortality rate among individuals with chronic widespread musculoskeletal complaints”. This 
put emphasis on a pooled unadjusted MRR of 1.69 which was not statistically significant, and a 
markedly reduced excess  (MRR 1.13) after full adjustment. The inclusion of UK Biobank, considering 
                                                          
3 We note that the data included in the Smith et al [10] meta-analysis for the study of McBeth et al [3], do not 
correspond to the data in the original manuscript.   
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age- and sex- adjusted risks, has provided a similar pooled estimate of excess risk (MRR 1.59) and is 
now statistically significant.  
 
We conclude that the evidence is now clear that persons with CWP experience excess mortality. UK 
Biobank results considerably reduce uncertainty around the magnitude excess risk, demonstrate 
that the risk is unlikely to be due to the experience of pain per se, but is substantially explained by 
lifestyle factors associated with having pain (poor diet, low levels of physical activity, smoking, high 
BMI). These provide important targets for intervention in managing patients with CWP. Optimal 
management of fibromyalgia should include exercise, but this is often not provided in a structured 
and supported way to facilitate long-term behaviour change. Few patients with CWP or fibromyalgia 
receive specific supported care in improving diet or stopping smoking. The data from this study 
shows that changing the habits of persons with CWP to be similar to persons without CWP could 
reduce mortality by around 35%. Such approaches should have high priority in the routine care of 
such patients.  
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Table 1: Characteristics of persons with CWP and no chronic pain in UK Biobank study 
Characteristic CWP 
(n= 7,130) 
No chronic pain 
(n=281,718 ) 
Died during follow-up (n, %) 405 (5.7%) 6,493 (2.3%) 
Died in first two years of follow-up (n,%) 95 (1.3%) 1,224 (0.4%) 
Age (median years, IQR) 58 (50, 63) 58 (52, 63) 
Sex (% male) 2,586 (36.3%) 135,186 (50.0%) 
Body Mass Index (kgm-2) 
- underweight (< 18.5) 
- normal (18.5-24.9) 
- overweight (25.0-29.9) 
- obese (30.0-34.9) 
- obese (35.0-39.9) 
- obese (≥ 40.0) 
 
44 (0.6%) 
1,354 (19.0%) 
2,572 (36.1%) 
1,761 (24.7%) 
799 (11.2%) 
600 (8.4%) 
 
1,609 (0.6%) 
101,010 (35.9%) 
121,141 (43.0%) 
43,088 (15.3%) 
10,364 (3.7%) 
4,506 (1.6%) 
Physical Activity (mean mins/week; sd): 
- walking 
- moderate activity 
- vigorous activity 
 
350 (579) 
276 (543) 
72 (275) 
 
363 (511) 
270 (444) 
93 (192) 
Physical Activity (climbing stairs per day) 
- None 
- 1-5 times 
- 6-10 times 
- 11-15 times 
- 16-20 times 
- >20 times 
 
1,223 (18.5%) 
2,158 (32.6%) 
1,795 (27.1%) 
720 (10.9%) 
378 (5.7%) 
346 (5.2%) 
 
22,451 (8.1%) 
53,163 (19.1%) 
103,353 (37.2%) 
53,779 (19.4%) 
25,048 (9.0%) 
20,071 (7.2%) 
Smoking status (n,%) 
- current smoker 
- ex-regular smoker 
- ex-occasional smoker 
- never or v. rarely 
 
1,316 (18.6%) 
1,779 (25.1%) 
627 (8.9%) 
3,360 (47.4%) 
 
26,241 (9.3%) 
61,161 (21.8%) 
32,581 (11.6%) 
160,839 (57.3%) 
Diet: fruit and vegetable consumption (median 
portions/day, IQR) 
 
8 (5, 11) 
 
7 (5, 10) 
Alcohol consumption (n, %) 
- daily or almost daily 
- 3-4 times/week 
- 1-2 times/week 
- < 1 time/week 
- Never 
 
767 (10.8%) 
842 (11.8%) 
1,485 (20.9%) 
2,407 (33.8%) 
1,616 (22.7%) 
 
60,829 (21.6%) 
69,667 (24.7%) 
74,096 (26.3%) 
58,139 (20.7%) 
18,789 (6.7%) 
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Table 2: Relationship between demographic and lifestyle factors and risk of death 
Characteristic Status at end of 
follow-up 
Restricted model: 
Mortality Risk 
Ratio  
(95% Cl)4 
Multivariable 
model:  
Mortality Risk 
Ratio  
(95% CI)5 
Alive (n) Dead (n)6 
Pain status 
- CWP 
- no chronic pain  
 
6,725 
275,225 
 
310 
5,269 
 
2.43 (2.17, 2.72) 
Reference 
 
1.47 (1.24, 1.73) 
Reference 
Age group (years) 
- <45 
- 45-49 
- 50-54 
- 55-59 
- 60-64 
- >64 
 
31,373 
38,228 
43,174 
51,083 
67,884 
50,538 
 
189 
353 
590 
1,021 
2,078 
2,667 
 
Reference 
1.60 (1.37, 1.87) 
2.50 (2.17, 2.89) 
3.80 (3.32, 4.36) 
5.61 (4.92, 6.39) 
9.09 (7.98, 10.4) 
 
 
Reference 
1.60 (1.25, 2.07) 
2.46 (1.95, 3.11) 
3.61 (2.90, 4.51) 
5.59 (4.51, 6.92) 
8.91 (7.20, 11.0) 
Sex 
- Male 
- Female 
 
133,453 
148,497 
 
4,319 
2,579 
 
Reference 
0.58 (0.56, 0.60) 
 
Reference 
0.59 (0.55, 0.63) 
Body Mass Index (kgm-2) 
- underweight (< 18.5) 
- normal (18.5-24.9) 
- overweight (25.0-29.9) 
- obese (30.0-34.9) 
- obese (35.0-39.9) 
- obese (≥ 40.0) 
 
1,569 
100,295 
120,888 
43,579 
10,784 
4,835 
 
84 
2,069 
2,825 
1,270 
379 
271 
 
1.86 (1.40, 2.50) 
Reference 
1.70 (1.59, 1.82) 
3.20 (2.98, 3.43) 
5.54 (5.08, 6.03) 
9.02 (8.23, 9.89) 
 
2.73 (2.07, 3.60) 
Reference 
0.93 (0.86, 1.01) 
1.11 (1.01, 1.22) 
1.35 (1.16, 1.58) 
1.94 (1.59, 2.36) 
Physical Activity: walking 
(mins/week) 
- 0 
- 1-100 
- 101-210 
- 211-420 
- >420 
Physical activity: moderate 
(mins/week) 
- 0 
- 1-60 
- 61-150 
- 151-360 
- >360 
Physical activity: vigorous 
(mins/week) 
- 0 
- 1-40 
- 41-90 
- 91-180 
 
 
5,150 
63,711 
74,315 
58,945 
46,710 
 
 
32,562 
60,247 
51,037 
51,640 
49,171 
 
 
94,509 
45,581 
40,814 
39,355 
 
 
225 
1,547 
1,778 
1,312 
1,017 
 
 
1,127 
1,221 
1,086 
1,086 
1,229 
 
 
3,068 
915 
729 
678 
 
 
4.15 (3.77, 4.57) 
Reference 
0.73 (0.68, 0.79) 
0.64 (0.59, 0.69) 
0.85 (0.79, 0.92) 
 
 
2.95 (2.74, 3.19) 
Reference 
0.91 (0.83, 0.99) 
0.87 (0.79, 0.95) 
1.30 (1.20, 1.42) 
 
 
Reference 
0.37 (0.34, 0.40) 
0.30 (0.28, 0.33) 
0.27 (0.24, 0.30) 
 
 
1.19 (0.99, 1.43) 
Reference 
0.98 (0.90, 1.07) 
0.92 (0.83, 1.01) 
0.89 (0.79, 0.99) 
 
 
1.14 (1.02, 1.27) 
Reference 
0.99 (0.90, 1.10) 
0.98 (0.88, 1.10) 
1.09 (0.97, 1.22) 
 
 
Reference 
0.77 (0.69, 0.85) 
0.78 (0.70, 0.87) 
0.76 (0.68, 0.85) 
                                                          
4 Adjusted for age and/or sex as applicable and excluding first two years of follow-up 
5 All variables entered in to the statistical model and mutually adjusted 
6 Deaths within two years of the baseline assessment are excluded  
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- >180 
Physical activity: stairs 
(times/day) 
- 0 
- 1-5 
- 6-10 
- 11-15 
- 16-20 
- >20 
33,648 
 
 
22,789 
53,707 
102,928 
53,420 
24,986 
20,011 
645 
 
 
885 
1,614 
2,220 
1,079 
440 
406 
0.43 (0.39, 0.47) 
 
 
1.29 (1.20, 1.38) 
Reference 
0.43 (0.41, 0.46) 
0.33 (0.30,0.36) 
0.37 (0.33, 0.41) 
0.42 (0.38, 0.47) 
0.79 (0.70, 0.89) 
 
 
1.02 (0.91, 1.14) 
Reference 
0.83 (0.76, 0.91) 
0.86 (0.77, 0.95) 
0.69 (0.60, 0.80) 
0.92 (0.80, 1.07) 
Smoking status 
- current smoker 
- ex-regular smoker 
- ex-occasional smoker 
- never or v. rarely 
 
26,309 
60,770 
32,532 
161,432 
 
1,248 
2,170 
676 
2,767 
 
2.54 (2.39, 2.70) 
1.44 (1.36, 1.52) 
0.92 (0.85, 1.003) 
Reference 
 
2.31 (2.10, 2.54) 
1.55 (1.43, 1.67) 
1.09 (0.97, 1.22) 
Reference 
Alcohol consumption 
- daily or almost daily 
- 3-4 times/week 
- 1-2 times/week 
- <1 time/week 
- Never 
 
59,954 
69,132 
73,949 
59,073 
19,639 
 
1,642 
1,377 
1,632 
1,473 
766 
 
Reference 
0.96 (0.87, 1.06) 
1.57 (1.44, 1.72) 
3.08 (2.84, 3.34) 
6.18 (5.68, 6.73) 
 
Reference 
0.92 (0.84, 1.02) 
0.97 (0.88, 1.07) 
1.08 (0.98, 1.20) 
1.49 (1.32, 1.69)) 
Diet: fruit and vegetable 
consumption 
- Lowest consumption 
- Quintile 2 
- Quintile 3 
- Quintile 4 
- Highest consumption 
 
 
62,641 
58,079 
25,448 
50,750 
40,733 
 
 
1,802 
1,363 
569 
1,156 
881 
 
 
Reference 
0.74 (0.69, 0.80) 
0.78 (0.71, 0.86) 
0.75 (0.69, 0.80) 
1.01 (0.94, 1.09) 
 
 
Reference 
0.90 (0.82, 0.98) 
0.88 (0.78, 0.99) 
0.88 (0.80, 0.97) 
0.86 (0.77, 0.95) 
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Table 3: Relationship between pain status and risk of death, adjusting for potential mediating 
variables 
 
Variables added to basic 
model7 
Participants8 
included in model 
(N) 
MRR9 (95% Cl): 
CWP v. no chronic 
pain 
MRR (95% CI) CWP 
v. no chronic pain 
(participants with 
full data)10 
No additional variables 287,529 2.43 (2.17, 2.72) 2.23 (1.90, 2.62) 
+ Body Mass Index 
category11 
287,529 2.13 (1.90, 2.39) 1.98 (1.68, 2.33) 
+ Physical activity: walking 253,579 2.09 (1.82, 2.40) 2.08 (1.76, 2.44) 
+ Physical activity: moderate 249,309 2.23 (1.96, 2.54) 2.06 (1.75, 2.42) 
+ Physical activity: vigorous 258,755 2.22 (1.97, 2.51) 2.01 (1.71, 2.36) 
+ Physical activity: stairs 283,221 2.12 (1.88, 2.38) 2.07 (1.76, 2.43) 
+ Smoking 286,590 2.16 (1.94, 2.42) 2.01 (1.71, 2.37) 
+ Diet: alcohol consumption 287,320 2.21 (1.97, 2.47) 2.05 (1.74, 2.41) 
+ Diet: fruit and vegetables 242,346 2.30 (2.02, 2.60) 2.21 (1.88, 2.60) 
Full multivariable model12 193,676 1.47 (1.24, 1.73) 1.47 (1.24, 1.73) 
 
                                                          
7 Pain status (chronic widespread pain v. no chronic pain), age and sex are entered in all models 
8 Deaths occurring within two years of the baseline assessment are excluded  
9 Mortality Risk Ratio 
10 Restricted to 193,676 participants with data on all variables included in the full model 
11 Each line represents the basic model with the addition of the single variable stated 
12 All additional variables entered into model: age, sex, body mass index, physical activity (walking, moderate 
and vigorous activities, climbing stairs), diet (fruit and vegetable, alcohol consumption), smoking status 
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Table 4: Studies eligible for meta-analysis of chronic widespread pain and mortality 
Study 
(Location) 
Sampling 
Frame 
Pain 
phenotype 
Pain 
phenotype 
prevalence  
Deaths 
(n)/ 
Study (n)  
Follow-up 
(years)  
Andersson, 
2009 
(Sweden) 
Random 
sample in 2 
municipalities  
>4 pain 
locations 
representing 
both the upper 
and lower body 
and including 
axial pain  
9.4% 189/1609 14 
Åsberg et al, 
2016 
(Norway) 
All 
inhabitants of 
one county 
CWP 
modified13 
definition in 
ACR 1990 
criteria of FM   
23.1% 12521/ 
65026 
14 
Macfarlane 
et al, 2001 
(UK) 
Persons 
registered 
with GP in 2 
areas  
Widespread 
pain according 
to  definition in 
ACR 1990 
criteria of FM 
15.3% 654/6569 8 
Macfarlane 
et al, 201714 
(UK) 
Persons aged 
40-69 
registered 
with GP in 22 
areas 
“Pain all over 
the body” 
lasting ≥3 
months 
1.4%  12799/ 
288848 
7 
McBeth et al, 
2009 (UK) 
Age- and sex-
stratified 
sample from 
3 GPs in one 
region 
Widespread 
pain definition 
in ACR 1990 
criteria of FM 
16.9% 1017/ 
4344 
8 
Nitter and 
Forseth, 
2013 
(Norway) 
Women born 
1940-69 in 
one town  
Pain in muscles 
and joints and 
back,  or pain 
in whole body, 
lasting ≥3 
months 
12.9% 89/2038 18 
ACR = American College of Rheumatology, CWP = Chronic widespread pain, GP = General 
practitioner, FM = fibromyalgia 
 
 
 
 
 
                                                          
13 There was no requirement to have pain on both sides of the body 
14 Current analysis 
